Clinical Trial Update: A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma [Phase 3]

View source ↗

Summary

A Phase 3 non-inferiority trial evaluating the efficacy, safety, and tolerability of the combination inhaler FSC (fluticasone propionate/salmeterol) 250/50 mcg …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Fluticasone propionate/Salmeterol (FSC) 250/50 mcg (fluticasone propionate/salmeterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2015-10-08